An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.

这项为期3年的延伸研究旨在为参与III期临床试验（phase III study）CAIN457F2305（该试验被定义为"核心研究"）的强直性脊柱炎（ankylosing spondylitis）患者提供司库奇尤单抗（secukinumab）预充式注射器（prefilled syringes, PFS）给药方案，并额外收集司库奇尤单抗长期给药期间临床获益、安全性及耐受性的可持续性相关数据。